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Cardiac Myosin-Binding Protein C Mutations and
Hypertrophic Cardiomyopathy
Haploinsufficiency, Deranged Phosphorylation,
and Cardiomyocyte Dysfunction
Sabine J. van Dijk, MSc; Dennis Dooijes, PhD; Cris dos Remedios, PhD; Michelle Michels, MD, PhD;
Jos M.J. Lamers, PhD; Saul Winegrad, PhD; Saskia Schlossarek, PhD; Lucie Carrier, PhD;
Folkert J. ten Cate, MD, PhD; Ger J.M. Stienen, PhD; Jolanda van der Velden, PhD
Background— Mutations in the MYBPC3 gene, encoding cardiac myosin-binding protein C (cMyBP-C), are a frequent
cause of familial hypertrophic cardiomyopathy. In the present study, we investigated whether protein composition and
function of the sarcomere are altered in a homogeneous familial hypertrophic cardiomyopathy patient group with
frameshift mutations in MYBPC3 (MYBPC3mut).
Methods and Results— Comparisons were made between cardiac samples from MYBPC3 mutant carriers (c.2373dupG,
n7; c.2864_2865delCT, n4) and nonfailing donors (n13). Western blots with the use of antibodies directed against
cMyBP-C did not reveal truncated cMyBP-C in MYBPC3mut. Protein expression of cMyBP-C was significantly reduced
in MYBPC3mut by 335%. Cardiac MyBP-C phosphorylation in MYBPC3mut samples was similar to the values in donor
samples, whereas the phosphorylation status of cardiac troponin I was reduced by 845%, indicating divergent
phosphorylation of the 2 main contractile target proteins of the -adrenergic pathway. Force measurements in
mechanically isolated Triton-permeabilized cardiomyocytes demonstrated a decrease in maximal force per cross-
sectional area of the myocytes in MYBPC3mut (20.22.7 kN/m2) compared with donor (34.51.1 kN/m2). Moreover,
Ca2 sensitivity was higher in MYBPC3mut (pCa505.620.04) than in donor (pCa505.540.02), consistent with
reduced cardiac troponin I phosphorylation. Treatment with exogenous protein kinase A, to mimic -adrenergic
stimulation, did not correct reduced maximal force but abolished the initial difference in Ca2 sensitivity between
MYBPC3mut (pCa505.460.03) and donor (pCa505.480.02).
Conclusions— Frameshift MYBPC3 mutations cause haploinsufficiency, deranged phosphorylation of contractile proteins,
and reduced maximal force-generating capacity of cardiomyocytes. The enhanced Ca2 sensitivity in MYBPC3mut is due
to hypophosphorylation of troponin I secondary to mutation-induced dysfunction. (Circulation. 2009;119:1473-1483.)
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Familial hypertrophic cardiomyopathy (FHCM) is themost frequent inheritable cardiac disease with a preva-
lence of 0.2%.1,2 FHCM-causing mutations are identified in
13 genes encoding sarcomeric proteins.3 Mutations in the
MYBPC3 gene encoding cardiac myosin-binding protein C
(cMyBP-C) represent 40% of all FHCM cases.4 Most
MYBPC3 mutations are predicted to produce C-terminally trun-
cated proteins, lacking titin and/or major myosin-binding
sites.4–6 Studies in FHCM patients carrying a MYBPC3 muta-
tion failed to reveal truncated cMyBP-C protein,7–9 suggesting
that MYBPC3 mutations may lead to haploinsufficiency.
Clinical Perspective p 1483
Evidence suggests that the first step in the pathogenesis of
FHCM involves mutation-induced sarcomeric dysfunction.2,3
Myocardial dysfunction in this group of patients has been
attributed at least partly to myocyte hypertrophy, disarray,
and interstitial fibrosis.10 However, direct evidence for both
reduced cMyBP-C expression and sarcomeric dysfunction in
MYBPC3 mutant carriers is missing.
Approximately 35% of the FHCM patients in the Nether-
lands have founder mutations in the MYBPC3 gene
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(c.2373dupG and c.2864_2865delCT)11 that both are pre-
dicted to encode C-terminally truncated proteins (Figure 1).8,9
This allowed us to investigate whether truncating mutations
in the MYBPC3 gene alter sarcomeric protein composition
and function in a rather homogeneous patient group. Cardiac
MyBP-C mRNA and protein expression and phosphorylation
status of sarcomeric proteins were analyzed in concert with
cardiomyocyte function in MYBPC3 mutation carriers and
compared with nonfailing donor samples.
Methods
Cardiac Biopsies
Cardiac tissue was obtained from the left ventricular (LV) septum of
11 patients with a founder mutation11,12 in the MYBPC3 gene
encoding cMyBP-C (MYBPC3mut: c.2373dupG, n7; 32 to 69 years
of age, mean 505 years; 2/5 male/female; c.2864_2865delCT,
n4; 32 to 62 years of age, mean 446 years; 2/2 male/female), who
underwent alcohol ablation or myectomy to relieve LV outflow
obstruction. Echocardiographic and clinical data of the patients are
given in the Table. Hypertrophic obstructive cardiomyopathy was
evident from increased septal thickness (211 mm; normal value
13 mm)13 and high LV transaortic pressure gradient
(786 mm Hg; normal value 30 mm Hg).14 LV ejection fraction
was moderately depressed (442%). Both mutations encode for
slightly different C-terminally truncated proteins with a theoretical
mass of 93 and 116 kDa for c.2373dupG8 and c.2864_2865delCT,9
respectively (Figure 1).15,16
Nonfailing cardiac tissue from the free LV wall was obtained from
donor hearts (n13; 13 to 65 years of age, mean 345 years; 10/3
male/female) when no suitable transplant recipient was found. The
donors had no history of cardiac disease, a normal cardiac exami-
nation, normal ECG, and normal ventricular function on echocardi-
ography within 24 hours of heart explantation. It should be noted that
the donor group was slightly younger and included relatively more
males than the FHCM group.
All samples were immediately frozen and stored in liquid nitro-
gen. The study protocol was approved by the local ethics commit-
tees, and written informed consent was obtained.
Quantitative mRNA Analyses
Total RNA was extracted from 5 to 40 mg of 4 nonfailing and 4
FHCM frozen cardiac tissues with the use of the SV Total RNA
A
B
C0 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10MyBP-C
Titin binding region
Myosin (S2) binding region
Phosphorylation
sitesCardiacspecific
domain Ig-like domain FN3 domain
Myosin (LMM) binding region
Truncated protein
c.2373dupG
Truncated protein
c.2864_2865delCT
23 24 25 26 275’ 3’
c.2373dupG c.2864_2865delCT
Mutated allel
Mutated RNA 23 24 25 26 27
c.2373dupG c.2864_2865delCT
5’ 3’
C0 C1 C2 C3 C4 C5MyBP-C
C0 C1 C2 C3 C4 C5 C6 C7 C8MyBP-C
Figure 1. A, Schematic representation of
cMyBP-C structure and MYBPC3 mutations.
cMyBP-C consists of 8 immunoglobin (Ig)-like
and 3 fibronectin (FN3) domains,15,16 with bind-
ing sites for myosin and titin. The N-terminal
C0 is specific for cMyBP-C, as is the MyBP-C–
like motif between C1 and C2, which contains
3 phosphorylation sites. B, Localization of the
mutations in cMyBPC. The c.2373dupG muta-
tion creates a splice donor site, resulting in
reading frame shift.8 Consequently, the
C-terminus of the protein is altered and termi-
nated after the C5 region, leading to a protein
with a predicted weight of 93 kDa. The CT
deletion in exon 27 (c.2864_2865delCT)9 cre-
ates a premature termination codon in exon 29,
which is located 42 bp upstream of the 3 end.
The expected truncated protein of 116 kDa
contains 1049 amino acids including 89 new
ones and a termination of the translation at the
end of the C8 domain.
Table. Patient Characteristics
Mutation Age, y Sex, M/F
LV Transaortic Pressure
Gradient, mm Hg ST, mm LVEDD, mm LVESD, mm LVEF, % Medication
c.2373dupG 32 F 100 30 40 20 50 -Blocker
c.2373dupG 39 F 60 20 38 21 45 CCB, diuretics
c.2373dupG 45 F 94 20 40 20 50 CCB
c.2373dupG 62 M 64 23 39 22 44 ATII, -blocker, statins
c.2373dupG 44 F 60 17 42 24 43 CCB
c.2373dupG 69 M 74 19 44 30 32 -Blocker, diuretics, statins
c.2373dupG 57 F 74 24 41 20 51 -blocker
c.2864_2865delCT 39 M 116 23 48 26 46 CCB, vitamin D, calcium
c.2864_2865delCT 44 M 70 20 40 25 38 CCB, -blocker
c.2864_2865delCT 62 F 67 15 39 24 38 -Blocker, diuretics, statins,
antiarrhythmic agent
c.2864_2865delCT 32 F 121 23 44 21 52 -Blocker, CCB, diuretics
M/F indicates male/female; ST, septal thickness; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; LVEF, LV ejection fraction, calculated as
(LVEDDLVESD)/LVEDD	100%; CCB, calcium channel blocker; and ATII, angiotensin II receptor antagonist.
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Isolation kit (Promega, Madison Wis) according to the manufactur-
er’s instructions. RNA concentration, purity, and quality were
determined with the use of the NanoDrop ND-1000 spectrophotom-
eter (Thermo Scientific, Waltham, Mass). Reverse transcription was
performed with the use of oligo-dT primers with the Superscript III
(Invitrogen, Carlsbad, Calif) from 50 to 100 ng RNA. Quantitative
determination of wild-type (WT) and mutant cMyBP-C mRNAs was
performed by real-time polymerase chain reaction with the TaqMan
ABI Prism 7900HT sequence detection system (Applied Biosystems,
Foster City, Calif) and TaqMan probes and primers specified as
follows (Figure 2A). For the c.2373dupG mutation, primers were
designed in exons 23 (F5-CCT CAC AGT CAA GGT CAT CG-3)
and 25 (R5-TCC ACC GGT AGC TCT TCT TC-3). Specific
TaqMan probes were designed to recognize either the WT mRNA in
exon 24 (F5-GAG CCG CCT GCC TAC GAT-3) or the mutant
mRNA at the junction between the smaller exon 24 (40 bp due to
the new cryptic donor splice site) and exon 25 (F5-GCA CAG TAC
AGG CTA CAT CCT G-3). For the c.2864_2865delCT mutation,
primers were designed in exons 27 (F5-AGT GCG GGC ACA CAA
TAT G-3) and 28 (R5-GGG ATG AGA AGG TTC ACA GG-3).
The WT probe recognized a WT sequence in exon 27 (F5-TGG
AGC CCC TGT TAC CAC C-3), and the mutant probe recognized
a mutant sequence (deleted of CT) in exon 27 (F5-CTG GAG CCC
GTT ACC ACC A-3). GAPDH was used as endogenous control to
normalize the quantification of the target mRNAs for difference in
the amount of cDNA added to each reaction. All analyses were
performed in triplicate with the software ABI 7900HT SDS 2.2. The
mRNA amount was estimated according to the comparative Ct
method with the 2-

Ct formula. The amount of both WT and
mutant mRNA was reported as the mean of the WT obtained from
the 4 nonfailing samples for each exon amplification.
Protein Analysis
Cardiac samples (11 MYBPC3mut, 8 donor) were treated with
trichloroacetic acid before protein analysis to preserve the endoge-
nous phosphorylation status of the sarcomeric proteins.17
Western Immunoblotting
Proteins were separated by 1-dimensional gel electrophoresis on a
15% polyacrylamide SDS gel and subsequently transferred to nitro-
cellulose paper by wet blotting. Polyclonal antibodies (diluted
1:1000) raised against recombinant C0C2, C5, and C8C9 produced
from human cDNA encoding cMyBP-C15 (Figure 1) were used for
detection of cMyBP-C (Dr S. Winegrad, University of Pennsylvania,
Philadelphia). Primary antibody binding was visualized with a second-
ary goat anti-rabbit antibody (diluted 1:2000) and enhanced chemilumi-
nescence (Amersham, GE Healthcare, Chalfont St. Giles, UK).
To detect truncated cMyBP-C, 2 antibodies were used, which are
directed to the N-terminal part of cMyBP-C (C0C2) and the middle
region of cMyBP-C (C5) (Figure 1). The sensitivity of the 2
antibodies to detect low amounts of truncated cMyBP-C under the
experimental conditions used was assessed with a dilution series of
a nonfailing donor sample (0.04 to 5 g). The dilution at which the
cMyBP-C band was still discernible was defined as the lower
detection limit and amounted to 1.6% (0.08 g) for the C0C2
antibody and 3.2% (0.16 g) for the C5 antibody (data not shown).
In addition, phosphorylation of cMyBP-C at Ser282 (P-cMyBP-C;
dilution 1:1000) and bisphosphorylation of cardiac troponin I (cTnI)
at Ser23/24 (ie, protein kinase A [PKA] sites, rabbit polyclonal
antibody; dilution 1:500; Cell Signaling, Danvers, Mass) were
analyzed and normalized to cMyBP-C (C0C2 antibody) and cTnI
(8I-7, mouse monoclonal antibody; dilution 1:6000, Spectral Diag-
nostics), respectively, to correct for differences in protein loading.
SYPRO Ruby and ProQ Diamond Staining of
Gradient Gels
Proteins were separated on 4% to 15% precast Tris-HCl gels
(Bio-Rad Laboratories, Hercules, Calif) and stained with SYPRO
Ruby and ProQ Diamond to determine sarcomeric protein levels and
phosphorylation, respectively, as described previously.17 The phos-
phorylation status of sarcomeric proteins was expressed relative to
-actinin, except when noted otherwise. Protein values of
MYBPC3mut are given as fraction (or percentage) of the value found
for donor samples, which was set to 1 (or 100%).
Isometric Force Measurements
Cardiomyocytes were mechanically isolated from small tissue sam-
ples as described previously.18 Triton-permeabilized cardiomyocytes
were glued between a force transducer and a piezoelectric motor and
stretched to a sarcomere length of 2.2 m. Force measurements
were performed at various calcium concentrations (pCa,
log10[Ca2], values ranging from 4.5 to 6.0) as described previous-
ly.18,19 Force measurements were performed in single cardiomyo-
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Figure 2. Detection and quantification of
mRNA by real-time polymerase chain reac-
tion. A, Scheme illustrating primers and
probes used in real-time polymerase chain
reaction with the Taqman system. mut indi-
cates mutant. B, The amount of mutant
mRNA was 20% of total cMyBP-C mRNAs
in both patient groups.
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cytes isolated from 10 MYBPC3mut (34 cardiomyocytes) and 13
donor samples (47 cardiomyocytes). On average, 2 to 5 cardiomyo-
cytes were studied for each patient/donor. One MYBPC3mut biopsy
was too small to isolate cardiomyocytes and was used for protein
analysis only. Cross-sectional area (width	depth	/4) of the car-
diomyocytes determined at a sarcomere length of 2.2 m was
significantly higher in MYBPC3mut (50867 m2) than in donor
(37426 m2). Length between the attachments did not significantly
differ and amounted to 625 m in MYBPC3mut and 724 m in
donor. Passive tension (Fpassive) was determined by shortening the cell
in relaxation solution (pCa 9.0) by 30% and immediately restretching
it to its original length. Maximal calcium activated tension (Factive [ie,
maximal force/cross-sectional area]) was calculated by subtracting
Fpassive from the total force (Ftotal) at saturating [Ca2] (pCa 4.5). Ca2
sensitivity is denoted as pCa50 (ie, pCa value at which 50% of Factive
is reached). Force measurements were repeated after incubation of
cells for 40 minutes at 20°C in relaxing solution containing the
catalytic subunit of PKA (100 U/mL, Sigma) or with the catalytic
domain of protein kinase C (PKC) (0.25 U/mL, Sigma).
Data Analysis
Data are presented as meanSEM. Cardiomyocyte force values
were averaged per sample, and mean values for MYBPC3mut and
donor samples were compared with unpaired Student t tests. Effects
of PKA/PKC were tested with 2-way ANOVA. P0.05 was con-
sidered significant. Asterisks denote significant difference between
MYBPC3mut and donor, and daggers denote significant difference
before versus after PKA/PKC treatment.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Reduced Mutant cMyBP-C mRNA Level in
FHCM Ventricular Tissue
To investigate whether both WT and mutant cMyBP-C
mRNAs were transcribed in FHCM ventricular tissues, real-
time reverse transcription polymerase chain reaction was
performed with the use of specific Taqman probes and
primers for each mutation (Figure 2A). The c.2373dupG
mutation was expected to induce a cryptic donor splice site in
exon 24 and the skipping of 40 nucleotides (Figure 1B). We
therefore designed WT and mutant probes accordingly. Sim-
ilarly, a specific mutant probe was designed for the 2864 to
2865 CT deletion in exon 27 and the corresponding WT
probe (Figure 2A). Mutant mRNA represented 23% and 20%
of the total cMyBP-C mRNA in c.2373dupG and
c.2864_2865delCT groups, respectively (Figure 2B). Because
both mutations result in a frameshift and a premature termi-
nation codon (Figure 1B), the data suggest that both nonsense
mutant mRNAs are partially subjected to degradation by the
nonsense-mediated mRNA decay.20
Reduced cMyBP-C Protein Level in FHCM
Ventricular Tissue
The presence of truncated cMyBP-C in MYBPC3mut patients
was examined by Western immunoblotting. After separation
by gel electrophoresis, proteins were transferred to nitrocel-
lulose and visualized with Ponceau (Figure 3A). Figure 3B
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Figure 3. cMyBP-C protein levels. A, Western
immunoblots were stained with Ponceau to
visualize proteins. MWM indicates molecular
weight marker. B, Western immunoblot using a
C0C2 antibody illustrates reduced expression
of full-length cMyBP-C (140 kDa) in cardiac
biopsies from MYBPC3mut patients compared
with donor. No traces were found of truncated
cMyBP-C (theoretical mass: 93 kDa
[c.2373dupG]; 116 kDa [c.2864_2865delCT]). C,
Representative cardiac samples on a gradient
gel stained with SYPRO Ruby (donor vs
MYBPC3mut). D, Relative expression of
cMyBP-C is significantly lower in MYBPC3mut
(n11) than in donor (n8). *P0.05.
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shows results with the use of an antibody directed against the
C0C2 region of cMyBP-C. None of the antibodies used
(against C0C2, C5, or C8C9) revealed truncated cMyBP-C
(predicted mass at 93 or 116 kDa) in any of the samples. On
the basis of the sensitivity of our Western immunoblot
analysis, levels of truncated cMyBP-C 1.6% could not be
detected. Hence, we cannot completely exclude the presence
of trace amounts of truncated cMyBP-C in MYBPC3mut.
However, overloading of MYPBC3mut samples (40 g; 8	
higher concentration) did not reveal protein bands at the
predicted mass (not shown), indicating the trace amounts of
truncated protein, if present, would be even 0.2%.
To determine the levels of full-length cMyBP-C, proteins
were separated by 1-dimensional gel electrophoresis and
stained with SYPRO Ruby (Figure 3C). The -actinin inten-
sity was used as loading control. The cMyBP-C/-actinin
protein ratio on the SYPRO Ruby–stained gels was 33%
lower in MYBPC3mut (n11) than in donor (n8) (Figure
3D). Western immunoblot analysis confirmed a reduced level
of full-length cMyBP-C (Figure 3B) in MYBPC3mut com-
pared with donor myocardium. On average, Western blot data
with the use of the C0C2 antibody showed a 23% lower
amount of cMyBP-C (normalized to Ponceau-stained actin on
the same blot) in MYBPC3mut compared with donor. How-
ever, the coefficient of variation of the Western immunoblot
analysis was much higher than that of SYPRO Ruby staining
(56.3% and 25.8%, respectively). Therefore, the SYPRO
values are considered to represent the protein levels more
accurately.
Deranged Phosphorylation
The SYPRO Ruby–stained gels were also stained with ProQ
Diamond, which selectively stains phosphorylated serine, thre-
onine, and tyrosine residues (Figure 4A). Phosphorylation of
cMyBP-C normalized to -actinin was reduced by 477% in
the MYBPC3mut compared with donor myocardium (P0.0001;
Figure 4B). Interestingly, phosphorylation of cMyBP-C normal-
ized to its own protein level (determined with SYPRO) was
similar between MYBPC3mut and donor myocardium (7911%
versus 1005%, respectively; P0.14; Figure 4C).
In addition, massive dephosphorylation of cTnI was ob-
served in MYBPC3mut relative to donor by 845%
(P0.0001; Figure 4D). Because the reduced ProQ Diamond
signals for cTnI in MYBPC3mut may be due to reduced cTnI
expression, we analyzed the steady state level of cTnI by
Western immunoblot. The amount of cTnI relative to
Ponceau-stained actin did not differ between MYBPC3mut and
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Figure 4. Phosphorylation status of
cMyBP-C and cTnI. A, ProQ Diamond–
stained gradient gel. MWM indicates molec-
ular weight marker. B, The phosphorylation
status of cMyBP-C (relative to SYPRO
Ruby–stained -actinin) is lower in
MYBPC3mut (n11) than in donors (n8),
whereas phosphorylation of cMyBP-C nor-
malized to its own expression level is com-
parable between MYBPC3mut and donors
(C). D, The phosphorylation status of cTnI
(relative to SYPRO Ruby–stained -actinin)
is lower in MYBPC3mut than in donors. E,
cTnI relative to Ponceau-stained actin did
not differ between MYBPC3mut and donor
myocardium. *P0.05.
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donor myocardium (Figure 4E). Hence, the reduced ProQ
Diamond signals represent reduced phosphorylation of cTnI
in MYBPC3mut compared with donor. Phosphorylation of
other sarcomeric proteins desmin, cardiac troponin T, and
myosin light chain 2 was also significantly reduced in
MYBPC3mut by 248%, 417%, and 614%, respec-
tively, relative to donor samples.
Western immunoblot analysis (Figure 5) revealed signifi-
cantly lower bisphosphorylation of PKA sites (Ser23/24) in
cTnI in MYBPC3mut compared with donors, whereas phosphor-
ylation of cMyBP-C at Ser282 was similar in MYBPC3mut and
donor myocardium. This confirms the data obtained with ProQ
Diamond stain (Figure 4).
Depressed Force Development
Functional implications of the MYBPC3 mutations were
investigated by cardiomyocyte force measurements in
c.2373dupG (n7; 25 cells) and c.2864_2865delCT (n3; 9
cells). A representative cardiomyocyte and a recording at
saturating Ca2 concentration (pCa 4.5) from a MYBPC3mut
patient are shown in Figure 6A and 6B. Maximal force devel-
opment (Factive) was significantly depressed in MYBPC3mut
(20.22.7 kN/m2) compared with donor (34.51.1 kN/m2; n13;
47 cells) (Figure 6C). Passive force (Fpassive) in MYBPC3mut
(3.80.7 kN/m2) was somewhat elevated compared with donor
(3.40.4 kN/m2), but the difference was not significant (Figure
6D). Interpatient variation in Factive and Fpassive in the MYBPC3mut
group was larger than in the donor group (Figure 6E, 6F). Factive
and Fpassive were lower in c.2864_2865delCT than in c.2373dupG
(PNS).
Cells from MYBPC3mut (c.2373dupG, n4, 9 cells;
c.2864_2865delCT; n2; 6 cells) and donors (n6; 18 cells)
were incubated with PKA,21 after which Factive and Fpassive
measurements were repeated to determine whether
-adrenergic stimulation could correct depressed force in
MYBPC3mut. PKA treatment resulted in a minor decrease in
Factive in MYBPC3mut (before versus after: 14.22.9 and
13.52.5 kN/m2), which was similar to the PKA effect in
donor (before versus after: 27.93.5 and 25.83.2 kN/m2)
(P0.03, 2-way ANOVA). Moreover, PKA significantly
decreased Fpassive in both groups (MYBPC3mut before versus
after: 2.30.3 and 2.10.2 kN/m2; donor before versus after:
3.30.5 and 2.70.4 kN/m2) (P0.001, 2-way ANOVA).
Because increased PKC activity/expression has been asso-
ciated with depressed maximal force generating capacity of
myofilaments,22 force measurements were repeated after
incubation with the catalytic domain of PKC. Factive in
MYBPC3mut (c.2373dupG; n3; 5 cells) was significantly
reduced after PKC by 2.60.6 kN/m2. A similar decrease
(3.30.7 kN/m2) was found in cardiomyocytes from donor
hearts (n5; 9 cells). PKC slightly decreased Fpassive in both
groups, although the effect was not significant (data not
shown).
Enhanced Ca2 Sensitivity
Ca2 sensitivity of the sarcomeres was significantly higher
in MYBPC3mut (pCa505.620.04) than in donor cells
(pCa505.540.02). The average force-pCa relationships ob-
tained in MYBPC3mut and donor cardiomyocytes are shown in
Figure 7A. Ca2 sensitivity was similar in c.2864_2865delCT
(pCa505.630.05) and c.2373dupG (pCa505.600.09).
Figure 7B illustrates that interpatient variation in pCa50 was
larger in the MYBPC3mut than in the donor group.
Treatment with exogenous PKA significantly reduced Ca2
sensitivity in both groups. The reduction in pCa50 was
significantly larger in MYBPC3mut (
pCa500.180.03) than
in donor (
pCa500.060.01) cells (Figure 7C). PKA treat-
ment abolished the initial difference in Ca2 sensitivity
between MYBPC3mut and donor (Figure 7D). ProQ Diamond
staining of a MYBPC3mut sample that was incubated without
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Figure 5. A, Western immunoblot analysis
with the use of a specific antibody against
cTnI phosphorylated at PKA sites (Ser23/24)
revealed reduced cTnI phosphorylation in
MYBPC3mut compared with donor myocardi-
um, whereas phosphorylation of cMyBP-C
at Ser282 did not differ between groups.
MWM indicates molecular weight marker.
B, Phosphorylation levels of cTnI and
cMyBP-C were normalized to total cTnI and
cMyBP-C protein expression, respectively.
*P0.05 MYBPC3mut vs donor.
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(control incubation) and with PKA showed a 4-fold increase
in cTnI phosphorylation, whereas the increase in cMyBP-C
phosphorylation was small (Figure 7E).
Similar to PKA, PKC significantly reduced pCa50 in both
groups. However, in contrast to PKA, the PKC-induced shift
in pCa50 did not significantly differ between MYBPC3mut
(
pCa500.110.04) and donor cells (
pCa500.080.01)
and thus does not explain the baseline difference in Ca2
sensitivity between MYBPC3mut and donor myocardium.
Discussion
Our study provides direct evidence for reduced cMyBP-C
protein level and contractile dysfunction in a group of FHCM
patients with MYBPC3 frameshift mutations. Consistent with
previous studies,7–9 no truncated cMyBP-C protein was de-
tected, and the amount of full-length cMyBP-C was 33%
lower in FHCM than in donor myocardium. Our data there-
fore indicate that the pathomechanism involves haploinsuffi-
ciency rather than a poison polypeptide. Using adenoviral
gene transfer of cardiomyocytes, Sarikas et al23 showed rapid
and quantitative degradation of truncated forms of cMyBP-C
by the ubiquitin-proteasome system, which could in turn
inhibit ubiquitin-proteasome system–mediated degradation of
other cellular proteins.23 Thus, the absence of truncated
cMyBP-C in FHCM patients in the present study suggests
that the ubiquitin-proteasome system may degrade truncated
cMyBP-C. The full-length C-protein, in contrast, compen-
sates for the absence of truncated protein. The fact that
mutant mRNAs were detected in both FHCM groups supports
the involvement of the ubiquitin-proteasome system in the
degradation of truncated protein. On the other hand, the lower
level of mutant versus WT cMyBP-C mRNA in both FHCM
groups suggests partial instability of nonsense mutant mRNA,
which could be degraded by the nonsense-mediated mRNA
decay.20
The maximum force-generating capacity (ie, Factive) of
cardiomyocytes from MYPBC3mut carriers was significantly
reduced by 42% compared with nonfailing myocardium.
Recent studies24–28 revealed an important role for cMyBP-C
in cross-bridge kinetics. Loss of cMyBP-C accelerates cross-
bridge cycling and impairs kinetics of contraction and relax-
ation.24,25,27 Complete knockout of cMyBP-C resulted in
profound cardiac hypertrophy and impaired contractile func-
tion in mice.29,30 Surprisingly, transgenic mice harboring only
40% of the normally expressed full-length cMyBP-C did not
have LV hypertrophy and showed preserved cardiac func-
tion.26 In contrast, our study shows that an 33% reduction
of full-length cMyBP-C level is sufficient to trigger LV
hypertrophy and contractile dysfunction in human. Intrigu-
ingly, reduced cMyBP-C levels per se do not seem to explain
the decline in maximum force in MYBPC3mut because Factive
Figure 6. Force measurements. Permeabil-
ized cardiomyocyte (A) and force recording
(B) of a MYBPC3mut sample. When a maxi-
mal steady force level was reached at satu-
rating [Ca2] (pCa4.5), the cell was quickly
shortened by 30% and immediately
restretched to its original length to deter-
mine the baseline of the force recording and
total force (Ftotal). Subsequently, the cell was
transferred to relaxing solution (pCa 9.0)
and shortened for a period of 10 seconds to
determine passive force (Fpassive). C, Active
force (Factive FtotalFpassive) in MYBPC3mut
was significantly depressed, and Fpassive (D)
was slightly but not significantly elevated
compared with donor. E and F, Variation
among mean force parameters of individu-
als among the MYBPC3mut group
(c.2373dupG, black symbols;
c.2864_2865delCT, gray symbols) com-
pared with the donor group (open symbols).
*P0.05.
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did not correlate with the level of full-length cMyBP-C (not
shown) but may rather involve reduced expression and
altered phosphorylation of cMyBP-C.
Cardiac MyBP-C is phosphorylated by PKA on adrenergic
stimulation.31 Apart from PKA, cMyBP-C can be phosphor-
ylated by Ca2-calmodulin–dependent kinase (CaMK)32,33
and PKC.34,35 Transgenic mice hearts in which the phosphor-
ylation sites of cMyBP-C were changed to nonphosphorylat-
able alanines displayed reduced contractility and altered
sarcomeric structure, indicating that phosphorylation of
cMyBP-C is essential for normal cardiac function.36 Reduced
cMyBP-C phosphorylation has been observed in animal
models of cardiac hypertrophy and failure36,37 and in humans
with end-stage idiopathic and ischemic cardiomyopathy.21,37
The discrepant phosphorylation levels of cMyBP-C and cTnI
in MYBPC3mut are in contrast to previous observations in
non-FHCM (idiopathic and ischemic cardiomyopathy) and
donor myocardium, which revealed parallel changes in the
main target proteins of the -adrenergic pathway.21,37 Hence,
it is possible that this discrepancy causes contractile dysfunc-
tion. Because PKA did not correct the reduction in Factive,
other (mal)adaptive signaling routes are responsible for di-
vergent phosphorylation of cMyBP-C and cTnI and sarco-
meric dysfunction. In a recent study, increased PKC expres-
sion level in 2 models of heart failure (pressure overload and
ischemic) in rat was associated with reduced maximal force-
generating capacity of myofilaments.22 To test whether this
applies to human tissue, force measurements were performed
in single human cardiomyocytes from MYBPC3mut and donor
hearts before and after incubation with PKC. The effects of
PKC on cardiomyocyte force parameters (Factive, Fpassive, and
pCa50) were similar in MYBPC3mut and donor cardiomyo-
cytes, indicating that impaired myofilament function in
MYBPC3mut does not seem to be related to a difference in
PKC-mediated phosphorylation of myofilament proteins.
Interestingly, Yuan et al38 revealed differential phosphor-
ylation of cMyBP-C on myocardial stunning and suggested
a role for altered calcium handling and activation of
CaMK. Thus, in combination with the evidence presented
in the literature, our experiments suggest that the reduced
Figure 7. A, Force measurements were per-
formed at maximal and submaximal [Ca2]
(pCa range 4.5 to 6). Force values obtained
in solutions with submaximal [Ca2] were
normalized to the maximal force level at
pCa 4.5. Force-pCa relations were fit to a
modified Hill equation. Ca2 sensitivity of
the sarcomeres (pCa50) was significantly
higher in MYBPC3mut than in donor. B, Vari-
ation among mean pCa50 parameters of
individuals among the MYBPC3mut group
(c.2373dupG, black symbols;
c.2864_2865delCT, gray symbols) com-
pared with the donor group (open symbols).
C, Treatment of cardiomyocytes with exog-
enous PKA induced a larger reduction in
pCa50 in MYBPC3mut than in donor. D, PKA
treatment abolished the initial difference in
Ca2 sensitivity between MYBPC3mut and
donor. *P0.05 MYBPC3mut vs donor;
†P0.05 before vs after PKA treatment. E,
ProQ Diamond staining of MYBPC3mut myo-
cardium, which was directly frozen (BL indi-
cates baseline) or incubated without PKA
(CTRL indicates control) or with PKA (100
U/mL). Phosphorylation of cTnI increased on
incubation with PKA. cTnT indicates cardiac
troponin T; MLC-2, myosin light chain 2.
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maximal force-generating capacity of cardiomyocytes is
not a direct consequence of haploinsufficiency but rather
might be caused by differential phosphorylation of cMyBP-C
resulting from (mal)adaptive neurohumoral signaling in
hearts of MYBPC3mut carriers.
Similarly, the higher Ca2 sensitivity of force development
in MYBPC3mut patients may be either a direct or an indirect
consequence of the cMyBP-C haploinsufficiency. Previous
studies of FHCM mutations in the thin-filament proteins
troponin and tropomyosin reported enhanced myofilament
Ca2 sensitivity in contrast to a reduction in Ca2 sensitivity,
which is considered characteristic for mutations found in
familial dilated cardiomyopathy.39–41 Robinson et al41 pro-
posed that the mutant-induced enhanced Ca2 sensitivity
reflects changes in Ca2 binding affinity, which may directly
alter Ca2 transient and trigger hypertrophic signaling
routes.42 Extraction of cMyBP-C by 30% to 70% from rat
cardiomyocytes resulted in an increase in Ca2 sensitivity.43,44
Similarly, a greater myofilament Ca2 sensitivity was found
in skinned myocytes at short sarcomere length from
cMyBP-C knockout mice,45 and a greater sensitivity to
external Ca2 was found in cMyBP-C knockout intact atrial
tissue.25 Hence, the frameshift MYBPC3 mutations inducing
cMyBP-C haploinsufficiency may directly increase Ca2
sensitivity. On the other hand, increased myofilament Ca2
sensitivity has also been found in end-stage failing human
myocardium (idiopathic dilated cardiomyopathy) without
known mutations in sarcomeric proteins.19,46,47 This enhanced
Ca2 sensitivity has been ascribed to hyperactivation of the
-adrenergic signaling pathway in response to reduced car-
diac pump function. Chronic activation of the -adrenergic
receptor pathway results in downregulation and desensitiza-
tion of the receptors in failing myocardium and a subsequent
parallel reduction in phosphorylation of the PKA target
proteins cMyBP-C and cTnI.17,21,37 In healthy myocardium,
the main effect of PKA-mediated phosphorylation of cTnI is
reduced Ca2 sensitivity, which contributes to appropriate
myocardial relaxation.27,48,49 Reduced phosphorylation of
cTnI and PKA-mediated increase in cTnI phosphorylation
and correction of Ca2 sensitivity to donor values in
MYBPC3mut suggest that heart failure–induced -adrenergic
desensitization underlies the increase in Ca2 sensitivity.
Hence, on the basis of our data, we postulate that the
enhanced Ca2 sensitivity of sarcomeres in MYBPC3mut is a
secondary consequence of the frameshift mutation-induced
cardiac dysfunction, which triggers adrenergic hyperactiva-
tion. The ensuing defects in -adrenergic signaling may
impair phosphorylation of Ca2 handling proteins, and sub-
sequent alterations in cellular Ca2 transient may activate
kinases, such as CaMK, involved in differential phosphory-
lation of cMyBP-C and cTnI.
Our data may be confounded by differences in medication
and in the origin of LV tissue (septum versus free wall).
Moreover, we cannot exclude that age and sex differences
affected our analysis. However, the unique MYBPC3 founder
mutations allowed us to characterize contractile properties in
a relatively homogeneous group of FHCM patients. The
combined analysis of sarcomere protein composition and
function revealed haploinsufficiency and reduced contractil-
ity in patients carrying a frameshift MYBPC3 mutation. The
sarcomeric phenotype in MYBPC3mut is the complex resultant
of the mutation and secondary alterations in the sarcomeric
phosphoproteome due to maladaptive alterations in neurohu-
moral signaling and/or Ca2 homeostasis. Therefore, our data
support the concept that contractile dysfunction is a pivotal
link between the mutant sarcomeric protein and pathological
hypertrophic cardiomyopathy.
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CLINICAL PERSPECTIVE
Familial hypertrophic cardiomyopathy is the most frequent inheritable cardiac disease, with a prevalence of 1/500.
Mutations in the MYBPC3 gene encoding cardiac myosin-binding protein C (cMyBP-C) represent 40% of all familial
hypertrophic cardiomyopathy cases. Cardiac MyBP-C is bound to the thick myosin filament and may influence binding of
the myosin head to actin and thereby force generation and pressure development of the heart. cMyBP-C function is
influenced by -adrenergic stimulation through protein kinase A–mediated phosphorylation. Most MYBPC3 mutations are
predicted to produce C-terminally truncated proteins, lacking titin and/or major myosin binding sites. Approximately 35%
of the familial hypertrophic cardiomyopathy patients in the Netherlands have founder mutations in the MYBPC3 gene that
encode C-terminally truncated proteins. This allowed us to investigate whether truncating mutations in MYBPC3 alter
sarcomeric protein composition and function in a rather homogeneous patient group. No truncated cMyBP-C was detected,
full-length cMyBP-C was reduced by 33% compared with nonfailing myocardium, and cMyBP-C phosphorylation was
preserved. Our data therefore indicate that the pathomechanism involves haploinsufficiency rather than a poison
polypeptide. Force measurements in single cardiomyocytes revealed reduced maximal force-generating capacity compared
with healthy cells. In addition, Ca2 sensitivity of the contractile apparatus was increased because of hypophosphorylation
of troponin I, another target of protein kinase A. We conclude that the sarcomeric phenotype in familial hypertrophic
cardiomyopathy with MYBPC3 mutations includes a primary contractile sarcomeric defect causing deranged secondary
alterations in protein phosphorylation. Our data therefore suggest that contractile dysfunction is a pivotal link between the
mutant sarcomeric protein and pathological hypertrophic cardiomyopathy.
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